- Mixed-methods pilot randomised controlled trial of 24 adults with knee osteoarthritis, combining quantitative feasibility data with semi-structured interviews.
- Participants were assigned to active or sham home-based tDCS plus an eight-week exercise program, with 10 stimulation sessions over two weeks.
- Adherence was high: 21/24 (88%) completed at least 75% of tDCS sessions, and no significant adverse events occurred. Mean pain intensity fell in both groups by week 8, from 47.3 to 28.3 (active) and 46.4 to 33.5 (sham).
- The authors concluded the approach was feasible, acceptable and well tolerated, and that a fully powered trial of 80 participants is warranted to test effects on pain and function.
Chronic pain
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Open-label multicentre randomised trial across 15 UK thoracic centres included 737 adults undergoing thoracotomy in the modified intention-to-treat population.
- The paravertebral group received three single-shot injections before incision plus a catheter, compared with a thoracic epidural catheter loaded with local anaesthetic before incision.
- Chronic post-thoracotomy pain at six months did not differ significantly, at 22% versus 16% (adjusted RR 1.32, 95% CI 0.93 to 1.86, P=0.12).
- Paravertebral blockade had less hypotension (12% vs 18%) and pruritus but more urinary retention (12% vs 6%), and day 1 acute pain was higher with paravertebral blockade.
AI summary not available. Read the source abstract on PubMed.
AI summary not available. Read the source abstract on PubMed.
- Randomized controlled trial of 90 healthy female participants, assigned to an open-label placebo group with choice, an open-label placebo group without choice, or a no-placebo control.
- Perceived pain was measured with transcutaneous electrical stimulation at baseline and after open-label placebo treatment or a waiting period.
- Open-label placebo reduced reported pain whether or not participants could choose the placebo type, and the choice group showed no preference for capsules, sprays, or colors.
- Higher positive superstition was linked to greater pain reduction in the placebo groups, while higher reported pain sensitivity showed the opposite pattern.
- Randomized equivalence trial of 84 adults with chronic non-specific low back pain and probable nociplastic features, conducted at a single rehabilitation department.
- Participants received weekly IV lidocaine (1 mg/kg bolus, then 4 mg/kg infusion over 4 weeks) or saline placebo, with all receiving amitriptyline and aerobic exercise.
- At 3 months, the VAS difference was 0.24 (90% CI -0.33 to 0.81), within the prespecified ±1.5 equivalence bounds (TOST P < .001); sleep quality favored lidocaine (mean difference 1.81; 95% CI 0.49-3.14; P = .027).
- The authors concluded lidocaine gave no additional analgesia over saline alongside multimodal care, and adverse events were more frequent with lidocaine but mild and transient.
AI summary not available. Read the source abstract on PubMed.
- Phase 2b randomized, double-blind, placebo-controlled dose-ranging trial in 110 participants after third molar extraction.
- Oral meloxicam formulation MR-107A-02 given at 1.25, 5, or 15 mg twice daily was compared with placebo.
- Mean SPID0-24 Emax values were 70.7, 86.7, and 94.8 across the doses, versus 52.0 for placebo; 5 and 15 mg were significant (p < .001).
- The 15 mg dose gave perceptible relief at 0.6 hours and meaningful relief at 1.5 hours, with the lowest rescue use (29.6%); authors report good tolerability.
- Secondary analysis of baseline data from 685 participants pooled from two clinical trials, with 44% living in rural areas and 96% female.
- Rurality and sociodemographic characteristics were examined as baseline factors associated with fibromyalgia severity and other symptom measures.
- FIQR was associated with age, race, marital status, education, employment, and income but not rurality (t = -0.350, P = 0.726), and sociodemographics explained R2 = 0.09 of FIQR variance.
- The authors conclude that sociodemographic factors and rurality had limited influence on fibromyalgia severity, pain, fatigue, and pain catastrophizing.
- Randomized within-patient trial of 48 adults (96 leads) receiving bilateral thoracic percutaneous spinal cord stimulator trial leads at one academic center.
- One lead in each patient was randomly anchored with Dermabond and the contralateral lead with suture, and upright radiographic migration was compared.
- Mean absolute migration was 9.15 mm with Dermabond versus 10.60 mm with suture (paired difference -1.46 mm, 95% CI -6.73 to 3.81; P = .58).
- Male sex and prior spine surgery predicted more migration, while fixation method did not; the authors call Dermabond clinically comparable to suture.
- Multicentre, randomised, double-blind trial in 873 analysed adults (914 randomised) undergoing video-assisted thoracoscopic lung resection.
- Perioperative low-dose esketamine (bolus at induction, then intra- and postoperative infusion for 48 h) was compared with normal saline.
- Chronic pain at 3 months was 14.7% with esketamine versus 21.2% with control (adjusted OR 0.62, 95% CI 0.43-0.90; P=0.013).
- A post hoc definition using NRS ≥3 during coughing also favoured esketamine (adjusted OR 0.39, 95% CI 0.19-0.84; P=0.015), and the authors report no increase in adverse effects.
- Randomized, double-blind, placebo-controlled crossover trial in 30 patients with chronic post-surgical peripheral neuropathic pain at a French university hospital.
- Participants took oral therapeutic-dose acetaminophen (3 g/day) or placebo for 7 days each, separated by a 7-day washout.
- Mean pain intensity did not differ from placebo (effect size -0.09, 95% CI -0.45 to 0.26, P = 0.607), and no secondary outcomes differed.
- The authors found no clinically meaningful short-term add-on analgesic benefit and no adverse events, and advised informing patients about the risks of long-term use.
- Pilot randomized, triple-blind trial of 36 patients undergoing bilateral total knee arthroplasty, split evenly across placebo, 400 mg, and 800 mg oral CBD groups.
- Four perioperative doses of oral CBD were compared with placebo, all given alongside standardized anesthesia and multimodal analgesia.
- Dunnett's testing found no significant difference in 72-hour opioid use versus placebo (400 mg: 144 vs 209 MME, p=0.10; 800 mg: 203.2 vs 209 MME, p=0.98).
- Post hoc testing showed lower opioid use with 400 mg (p=0.04), and the authors frame the findings as a potential signal that needs larger trials.
AI summary not available. Read the source abstract on PubMed.
- Single-blind randomized trial of 120 women aged 20-50 with mild to moderate chronic nonspecific low back pain, comparing three arms over 8 weeks.
- Compared CFT combined with Pilates against Pilates alone and a control group, with pain intensity as the primary outcome.
- Both Pilates-based arms outperformed control on pain, disability, and kinesiophobia, but CFT added no difference to Pilates for pain (p = 0.871) or disability (p = 1.000).
- CFT plus Pilates was superior for kinesiophobia (p = 0.001), trunk flexion endurance (p = 0.003), and lateral-flexion endurance (p = 0.001).
- Randomised, quadruple-blind trial of 90 patients aged 65-100 undergoing primary total knee arthroplasty, comparing dexamethasone adjuncts to adductor canal and iPACK blocks.
- Perineural dexamethasone (4 mg total, 2 mg per block) with ropivacaine was compared with intravenous dexamethasone 4 mg and with placebo.
- Median time to first rescue opioid was 4.5 h with placebo, 13.9 h with IV dexamethasone and 18.5 h with perineural dexamethasone (log-rank p < 0.001).
- Perineural dexamethasone produced lower opioid use than IV at later timepoints, and no motor weakness or nerve injury was reported.
- Randomized crossover trial of 48 people with nonspecific shoulder pain, comparing a blood flow restriction session with a sham-BFR session after a 7-day washout.
- Each session used low-load biceps curls with either BFR or sham-BFR, followed by a standardized shoulder exercise loading session.
- BFR produced larger immediate MVIC gains (EMD = 0.058, p < 0.05) and larger gains after loading (EMD = 0.042, p < 0.05) than sham; PPT rose only after BFR (infraspinatus EMD = 1.32; middle deltoid EMD = 1.27).
- The authors conclude that a single BFR session gave immediate, clinically meaningful pain reduction and strength gains, though both conditions reduced pain.